Navigation Links
InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
Date:2/7/2008

at or before the EASL meeting

and/or the Digestive Disease Week meeting. These meetings will take

place in April and May, respectively.

-- The company expects to initiate its 14-day triple combination study of

ITMN-191 in combination with Pegasys(R) and ribavirin, in the second

quarter of 2008. The study design and timeline will be shared at study

initiation.

-- An Investigational New Drug (IND) application is expected to be filed

by Roche for ITMN-191/R7227 in the second half of 2008 to gain FDA

approval to study the compound in the United States.

Conference Call and Webcast Details

InterMune will host a conference call today at 4:30 p.m. EST to discuss its financial results for the fourth quarter and full year 2007, its forward-looking financial guidance and its clinical development programs. Interested investors and others may participate in the conference call by dialing 888-799-0528 (U.S.) or 706-634-0154 (international), conference ID# 32601453. A replay of the webcast and teleconference will be available approximately three hours after the call.

To access the webcast, please log on to the company's website at http://www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 32601453. The webcast will remain available on the company's website until the next earnings call.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (I
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Calif. , July 29, 2014  ImmunoClin ... in personalized medicine, treatment of infectious diseases as ... of prognosis and prevention of pathologies like cardiovascular ... August 1, 2014, ImmunoClin Corporation will complete the ... Washington, D.C. , a key center ...
(Date:7/29/2014)... Tenn. (PRWEB) July 29, 2014 ... in biomass feedstock supply innovation and supply chain ... proprietary feedstock management systems, Energy Grange™ and Supply ... of R&D and in-the-field testing aimed at consolidating ... offering benefits to landowners, farmers and feedstock end ...
(Date:7/29/2014)... 2014  United Therapeutics Corporation (NASDAQ: ... results for the second quarter ended June 30, ... that our medicines are reaching increasing numbers ... (PAH)," said Martine Rothblatt, Ph.D., United Therapeutics, ... launch this quarter of our extended-release tablet ...
(Date:7/29/2014)... The prestigious "Discovery or Exploration in History Award" ... Juliana Hillis and Kaylie O’Connell, students at Stoneham High ... Egg, Everything: America’s First IVF Baby". This project was ... History Day program during a week-long final competition judged ... D.C. , The growing popularity of the assisted reproductive ...
Breaking Biology Technology:ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 2ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 3Genera Energy Introduces Proprietary Feedstock Management Systems 2Genera Energy Introduces Proprietary Feedstock Management Systems 3Genera Energy Introduces Proprietary Feedstock Management Systems 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 3
... CINCINNATI, June 16, 2011 Kendle (Nasdaq: ... research organization, today announced several of its senior ... issues at the Drug Information Association (DIA) 47th ... experts will address key topics, including the benefits ...
... , New Generation of the Ziehm Vision RFD ... Imaging has launched a new generation of the Ziehm Vision,RFD ... allows it to be used over an almost unlimited period,of ... ORs.,Thanks to its mobility and significantly lower investment costs,the Ziehm ...
... 2011 NewCardio, Inc., (OTC BB: NWCI) a ... of its recent medical and technical submissions have ... Annual International Conference of the IEEE Engineering in ... The two papers: ,Wireless Monitoring of Reconstructed 12-Lead ...
Cached Biology Technology:Kendle Experts to Address Key Industry Issues at Drug Information Association 47th Annual Meeting 2Kendle Experts to Address Key Industry Issues at Drug Information Association 47th Annual Meeting 3SVS 2011: Ziehm Imaging Presents Latest Mobile C-armTechnology for Intraoperative use 2NewCardio Selected to Present at 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society 2NewCardio Selected to Present at 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society 3NewCardio Selected to Present at 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society 4
(Date:7/28/2014)... pinpointed a mechanism in part of the brain that is ... to both type 1 and type 2 diabetes. The findings ... of the National Academies of Sciences . , "We,ve ... part of the hypothalamus known as the ventromedial nucleus ... levels in the blood," said lead author Sabrina Diano, professor ...
(Date:7/28/2014)... The genome of Solanum pennellii , a wild ... an international group of researchers including the labs headed ... UC Davis Department of Plant Biology. The new genome ... , The work, published July 27 in the journal ... and colleagues at Aachen University in Germany. The UC ...
(Date:7/28/2014)... for Alzheimer,s disease and other forms of dementia, but ... treatment. , University of Washington bioengineers have a designed ... of the body,s normal proteins into a state that,s ... disease, Type 2 diabetes and Lou Gehrig,s disease. The ... their normal state into an abnormally folded form by ...
Breaking Biology News(10 mins):Glucose 'control switch' in the brain key to both types of diabetes 2New protein structure could help treat Alzheimer's, related diseases 2New protein structure could help treat Alzheimer's, related diseases 3
... DigitalPersona, Inc., a leader in fingerprint identity ... Solutions Company is now offering U.are.U fingerprint sensors ... modular point-of-sale (POS) workstation, the Stingray JS-950. The ... can be attached to either side of the ...
... land degradation in dryland regions continuing to worsen, ... on scientist-recommended indicators for monitoring and assessing desertification ... landmark agreement was reached after two weeks of ... attending the Ninth Session of the Conference of ...
... Israel, October 7, 2009 H2 Blocker drugs, such as ... reflux (heartburn), pose no significant risks for the fetus according ... University of the Negev. The study published in the ... the safety of the fetus when H2 blocker drugs ...
Cached Biology News:Panasonic Offers U.are.U(R) Fingerprint Sensor From DigitalPersona on Stingray JS-950 Point-of-Sale Workstations 2Satellite data instrumental in combating desertification 2Satellite data instrumental in combating desertification 3Heartburn drugs deemed safe for fetuses according to Ben-Gurion University researchers 2
Purified Mouse anti-Hu LAT (pY226) Storage Temperature: Refrigerate(2 to 8C)...
Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile, Molecular Biology Grade...
... the most comprehensive, cost-effective solution to ... incorporated unprecedented quality into both our ... proven detection chemistries and antibodies that ... protocol. It also includes our competitively ...
...
Biology Products: